The Use of Memantine for Prevention of Alzheimer's Disease
As the US population ages, the prevalence of dementia is increasing, and Alzheimer's Disease (AD) is the most prevalent one. Solving the Alzheimer's Disease (AD) epidemic is likely to require preventive therapy beginning many years before symptoms are expected to be evident in at-risk individuals. AD is caused by the dysfunction, loss of synapses, and eventual neuronal death, which may occur up to 25 years before clinical symptoms appear. This study, based off of pre-clinical data, seeks to assess whether it is feasible to use memantine hydrochloride for the prevention of Alzheimer's Disease.
• Be between the age of 50 and 65 years at time of informed consent.
• Have a positive family history for dementia (minimum of 1 first degree relative).
• Previously known or documented heterozygote or homozygote ApoE ε4 allele.
• Be able to read and write and must have adequate hearing and visual acuity to complete the psychometric tests.
• Be otherwise healthy for their age group or medically stable with or without medication on the basis of physical examination, medical history, vital signs, and 12-lead ECG performed at screening or at baseline.
• Have Montreal Cognitive Assessment (MOCA) score of 27 or above.
• Have a creatinine clearance (CrCl), estimated using the Cockcroft-Gault formula, greater or equal to 30 mL/minute.